Related references
Note: Only part of the references are listed.A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells
David J. DiLillo et al.
BLOOD ADVANCES (2021)
A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor
Huilin Ma et al.
AAPS JOURNAL (2020)
Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody
Karin Staflin et al.
JCI INSIGHT (2020)
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer
Alison Crawford et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety
Diego Ellerman
METHODS (2019)
Design and Production of Bispecific Antibodies
Qiong Wang et al.
ANTIBODIES (2019)
A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies
Gregory Z. Ferl et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model
Danielle Mandikian et al.
MOLECULAR CANCER THERAPEUTICS (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Redirecting T cells to hematological malignancies with bispecific antibodies
Mireya Paulina Velasquez et al.
BLOOD (2018)
Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance
Young-Jun Park et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia
Steven R. Leong et al.
BLOOD (2017)
Recent advances of bispecific antibodies in solid tumors
Shengnan Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Humanized mouse model supports development, function, and tissue residency of human natural killer cells
Dietmar Herndler-Brandstetter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
Haleh Saber et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2017)
Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
Yariv Mazor et al.
SCIENTIFIC REPORTS (2017)
A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma
Madan M. Kwatra
CURRENT CANCER DRUG TARGETS (2017)
Mechanistic Projection of First-in-Human Dose for Bispecific Immunomodulatory P-Cadherin LP-DART: An Integrated PK/PD Modeling Approach
X. Chen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity
Andrew D. Tustian et al.
MABS (2016)
Targeting B-cell maturation antigen in multiple myeloma
Yu-Tzu Tai et al.
IMMUNOTHERAPY (2015)
Alternative molecular formats and therapeutic applications for bispecific antibodies
Christoph Spiess et al.
MOLECULAR IMMUNOLOGY (2015)
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
Eric J. Smith et al.
SCIENTIFIC REPORTS (2015)
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Shannon L. Maude et al.
CANCER JOURNAL (2014)
Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes
Lynn E. Macdonald et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice
Andrew J. Murphy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
David T. Teachey et al.
BLOOD (2013)
Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways
Donavon Hiss
JOURNAL OF ONCOLOGY (2012)
Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase
Simone Jeger et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2010)
Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients
Peter Ruf et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy
Diane Seimetz et al.
CANCER TREATMENT REVIEWS (2010)
Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine
Maria J. W. D. Vosjan et al.
NATURE PROTOCOLS (2010)
Computational design of antibody-affinity improvement beyond in vivo maturation
Shaun M. Lippow et al.
NATURE BIOTECHNOLOGY (2007)
Share Paper
